February 18th 2025
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.
University of Virginia Researchers Discover New Target to Prevent Vision Loss
March 24th 2023The discovery of a protein that determines levels of vascular endothelial growth factor-A (VEGF) could lead to new therapies for macular degeneration, diabetic retinopathy and other common causes of vision loss.
Read More
Eyelea is Shown to Be More Effective Than Avastin at Weaning nvAMD Patients off Treatments
December 8th 2022The early response to neovascular age-related macular degeneration (nvAMD) treatment with aflibercept (Eyelea) was much greater than the response to bevacizumab (Avastin), in hopes of weaning those affected off the therapies sooner.
Read More
Can Ocular Biomarkers Be Used to Diagnose Alzheimer’s Disease?
December 5th 2022In an umbrella review — a review of reviews — investigators found that so far, studies of ocular biomarkers to diagnose Alzheimer’s disease had important limitations. Longitudinal studies that use artificial intelligence could perhaps identify ocular biomarkers, the researchers suggest.
Read More